Skip to main content

Table 2 Baseline demographic, clinical characteristics, and treatment patterns of patients overall and stratified by age group

From: Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer

Parameters at index date

Eligible population N = 2175

Age group

Age <65, n = 846

Age 65–74, n = 759

Age ≥75, n = 570

Sex, n (%)

 Male

1169 (53.7)

439 (51.9)

412 (54.3)

318 (55.8)

 Female

1006 (46.3)

407 (48.1)

347 (45.7)

252 (44.2)

Histology, n (%)

 Nonsquamous

1447 (66.5)

597 (70.6)

507 (66.8)

343 (60.2)

   Adenocarcinoma only

1445 (66.4)

588 (69.5)

511 (67.3)

346 (60.7)

 Squamous

457 (21.0)

142 (16.8)

165 (21.7)

150 (26.3)

 Adenosquamous carcinoma

34 (1.6)

9 (1.1)

13 (1.7)

12 (2.1)

 NSCLC NOS

152 (7.0)

61 (7.2)

49 (6.5)

42 (7.4)

 Unknown

0

0

0

0

Stage, n (%)

 Stage 3

78 (3.6)

29 (3.4)

24 (3.2)

25 (4.4)

 Stage 4

2097 (96.4)

817 (96.6)

735 (96.8)

545 (95.6)

Number of metastatic sites, n (%)

 0

23 (1.1)

11 (1.3)

6 (0.8)

6 (1.1)

 1

1404 (64.6)

528 (62.4)

488 (64.3)

388 (68.1)

 2

504 (23.2)

214 (25.3)

176 (23.2)

114 (20.0)

 ≥3

173 (8.0)

69 (8.2)

66 (8.7)

38 (6.7)

 Missing

71 (3.3)

24 (2.8)

23 (3.0)

24 (4.2)

Evidence of visceral metastasisa, n (%)

 Present

1716 (78.9)

684 (80.9)

594 (78.3)

438 (76.8)

 Absent

459 (21.1)

162 (19.1)

165 (21.7)

132 (23.2)

Evidence of nonvisceral metastasis, n (%)

 Present

817 (37.6)

312 (36.9)

297 (39.1)

208 (36.5)

 Absent

1358 (62.4)

534 (63.1)

462 (60.9)

362 (63.5)

Evidence of brain metastasis, n (%)

 Present

499 (22.9)

248 (29.3)

165 (21.7)

86 (15.1)

 Absent

1676 (77.1)

598 (70.7)

594 (78.3)

484 (84.9)

Evidence of bone metastasis, n (%)

 Present

649 (29.8)

249 (29.4)

239 (31.5)

161 (28.2)

 Absent

1526 (70.2)

597 (70.6)

520 (68.5)

409 (71.8)

Evidence of liver metastasis, n (%)

 Present

289 (13.3)

108 (12.8)

112 (14.8)

69 (12.1)

 Absent

1886 (86.7)

738 (87.2)

647 (85.2)

501 (87.9)

ECOG PS group, n (%)

 0 or 1

1408 (64.7)

581 (68.7)

500 (65.9)

327 (57.4)

 2+

430 (19.8)

130 (15.4)

156 (20.6)

144 (25.3)

 Unknown

337 (15.5)

135 (16.0)

103 (13.6)

99 (17.4)

Line of therapy, n (%)

 1

2175 (100.0)

846 (100.0)

759 (100.0)

570 (100.0)

 2

531 (24.4)

256 (30.3)

188 (24.8)

87 (15.3)

 3

136 (6.3)

73 (8.6)

43 (5.7)

20 (3.5)

 ≥4

38 (1.7)

25 (3.0)

7 (0.9)

6 (1.1)

Smoking status, n (%)

 Yes (current smoker, former smoker)

1912 (87.9)

748 (88.4)

678 (89.3)

486 (85.3)

 No (never smoker)

263 (12.1)

98 (11.6)

81 (10.7)

84 (14.7)

History of autoimmune disease, n (%)

 Yes

33 (1.5)

12 (1.4)

13 (1.7)

8 (1.4)

 No

2142 (98.5)

834 (98.6)

746 (98.3)

562 (98.6)

Use of immunosuppressive medication, n (%)

 Yes

385 (17.7)

133 (15.7)

132 (17.4)

120 (21.1)

 No

1790 (82.3)

713 (84.3)

627 (82.6)

450 (78.9)

Patient is immunocompromised, n (%)b,c

 Yes

240 (11.0)

82 (9.7)

90 (11.9)

68 (11.9)

 No

1935 (89.0)

764 (90.3)

669 (88.1)

502 (88.1)

Patients with a RET test recorded, n (%)

1076 (49.5)

416 (49.2)

388 (51.1)

272 (47.7)

 Positive

73 (3.4)

28 (3.3)

26 (3.4)

19 (3.3)

Patients with a BRAF test recorded, n (%)

1280 (58.9)

499 (59.0)

458 (60.3)

323 (56.7)

 Positive

108 (5.0)

37 (4.4)

38 (5.0)

33 (5.8)

Patients with a MET exon 14 skipping mutation test, n (%)

1062 (48.8)

409 (48.3)

385 (50.7)

268 (47.0)

 Positive

0%

0

0

0

Patients with a RET, BRAF, or MET test recorded, n (%)

1307 (60.1)

509 (60.2)

466 (61.4)

332 (58.2)

 Positive

179 (8.2)

65 (7.7)

62 (8.2)

52 (9.1)

Patients with a PD-1/PD-L1 test recorded, n (%)

1566 (72.0)

612 (72.3)

545 (71.8)

409 (71.8)

 Unknown

90 (4.1)

36 (4.3)

32 (4.2)

22 (3.9)

 Negative

498 (22.9)

206 (24.3)

188 (24.8)

104 (18.2)

 Positive

978 (45.0)

370 (43.7)

325 (42.8)

283 (49.6)

   PD-1/PD-L1 expression 1–49%d

62 (2.9)

23 (2.7)

17 (2.2)

22 (3.9)

   PD-1/PD-L1 expression ≥50%d

115 (5.3)

47 (5.6)

35 (4.6)

33 (5.8)

Patients receiving anti–PD-1/PD-L1 monotherapy, n (%)

1103 (50.7)

379 (44.8)

361 (47.6)

363 (63.7)

 Atezolizumabe

58 (5.3)

17 (4.5)

18 (5.0)

23 (6.3)

 Nivolumabe

271 (24.6)

100 (26.4)

87 (24.1)

84 (23.1)

 Pembrolizumabe

774 (70.2)

262 (69.1)

256 (70.9)

256 (70.5)

Patients receiving anti–PD-1/PD-L1 therapy in combination with a platinum-based chemotherapy, n (%)

989 (45.5)

447 (52.8)

357 (47.0)

185 (32.5)

 Pembrolizumab + platinum-based chemotherapye

950 (96.1)

429 (96.0)

344 (96.4)

177 (95.7)

Patients receiving anti–PD-1/PD-L1 combined with any other therapy, n (%)

83 (3.8)

20 (2.4)

41 (5.4)

22 (3.9)

 Ipilimumab + nivolumabe

47 (56.6)

9 (45.0)

22 (53.7)

16 (72.7)

  1. BRAF proto-oncogene B-Raf, ECOG PS Eastern Cooperative Oncology Group performance status, HIV human immunodeficiency virus, MET mesenchymal epithelial transition factor, NOS not otherwise specified, NSCLC non-small cell lung cancer, PD-1 programmed cell death protein 1, PD-L1 programmed cell death ligand 1, RET RET proto-oncogene
  2. aPulmonary (lung), hepatic (liver), pleural, pleural effusions, peritoneal and ascites involvement. Patients with visceral metastases irrespective of the presence of any other metastatic sites (eg, bone) can be categorized as visceral. All other patients without visceral metastases can be categorized as nonvisceral
  3. bImmunocompromised defined as having HIV or taking long-term (≥30 days) immunosuppressive medications
  4. cHaving HIV, long-term use of prednisone/prednisolone, and long-term use of other immunosuppressive medications are not mutually exclusive
  5. dAt the time of analysis, the completeness/availability of expression results in the Patient360 NSCLC database was limited
  6. ePercentages reported are for the treatment subgroup, not the eligible patient population
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us